COMMUNIQUÉS West-GlobeNewswire

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
26/05/2026
SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
VVT Med Announces First Patients Treated with VVT’s ScleroSafe™ System in Italy
26/05/2026
Leading Italian Vein Specialist Dr. Luca Palombi and His Team Successfully Treat First Patients in Italy Using the ScleroSafe™ System VANCOUVER, BC, May 26, 2026 (GLOBE NEWSWIRE) -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" [...]
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
26/05/2026
Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40% Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier [...]
Kraig Biocraft Laboratories Smashes Production Targets as New Spider Silk Batch Surges Past Expectations
26/05/2026
Company Reports Record Early Production Results, Exceeding Yield Targets by 20% ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig' [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
26/05/2026
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for [...]
Brain Cancer Canada Invests $50,000 in Promising Immunotherapy Breakthrough Targeting One of the Most Aggressive Brain Tumours
26/05/2026
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide is proud to award $50,000 to an exciting [...]
Nu-Tek BioSciences accélère la révolution des matières premières sans origine animale et rejoint le pavillon du Minnesota #4507 au salon BIO 2026
26/05/2026
Nu-Tek BioSciences rejoint le pavillon du Minnesota organisé par le Minnesota Department of Employment and Economic Development (MN DEED) lors du salon BIO, du 22 au 25 juin à San Diego, en Californie, afin de présenter [...]
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
26/05/2026
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind, placebo- [...]
PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing
26/05/2026
New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight MENLO [...]
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
26/05/2026
Pratteln, Switzerland, May 26, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln [...]
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
26/05/2026
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common [...]
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
26/05/2026
Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its progress in [...]
MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL Q1 2026 FINANCIALS: REVENUE SURGES, EXPANSION ON TRACK, AND CEO TO SPEAK AT HEMP BEVERAGE EXPO
26/05/2026
MedX Holdings and the Lazydaze franchise momentum keeps building - The New Era After Cannabis Rescheduling Austin, Texas , May 26, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL [...]
LENZ Therapeutics to Participate in Upcoming Investor Conferences
26/05/2026
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44 [...]
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
26/05/2026
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an [...]
Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
26/05/2026
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic [...]
Nu-Tek BioSciences Fuels Animal-Free Raw Materials Revolution, Joins Minnesota Pavilion #4507 at BIO 2026
26/05/2026
Nu-Tek BioSciences joins the MN DEED Minnesota Pavilion at BIO, June 22-25 in San Diego, CA, offering biotech innovators a blueprint for scalable, animal-free manufacturing through its product portfolio and Variability [...]
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
26/05/2026
BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Annovis Bio Regains NYSE Listing Compliance
26/05/2026
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]

Pages